Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 145

1.

Clinical effects of natalizumab on multiple sclerosis appear early in treatment course.

Kappos L, O'Connor PW, Polman CH, Vermersch P, Wiendl H, Pace A, Zhang A, Hotermans C.

J Neurol. 2013 May;260(5):1388-95. doi: 10.1007/s00415-012-6809-7. Epub 2013 Jan 5.

2.

Natalizumab therapy for highly active pediatric multiple sclerosis.

Kornek B, Aboul-Enein F, Rostasy K, Milos RI, Steiner I, Penzien J, Hellwig K, Pitarokoili K, Storm van's Gravesande K, Karenfort M, Blaschek A, Meyer A, Seidl R, Debelic D, Vass K, Prayer D, Kristoferitsch W, Bayas A.

JAMA Neurol. 2013 Apr;70(4):469-75. doi: 10.1001/jamaneurol.2013.923.

PMID:
23420110
3.

Safety and efficacy of natalizumab in Belgian multiple sclerosis patients: subgroup analysis of the natalizumab observational program.

van Pesch V, Bartholomé E, Bissay V, Bouquiaux O, Bureau M, Caekebeke J, Debruyne J, Declercq I, Decoo D, Denayer P, De Smet E, D'hooghe M, Dubois B, Dupuis M, Sankari SE, Geens K, Guillaume D, van Landegem W, Lysandropoulos A, de Noordhout AM, Medaer R, Melin A, Peeters K, Ba RP, Retif C, Seeldrayers P, Symons A, Urbain E, Vanderdonckt P, Van Ingelghem E, Vanopdenbosch L, Vanroose E, Van Wijmeersch B, Willekens B, Willems C, Sindic C.

Acta Neurol Belg. 2014 Sep;114(3):167-78. doi: 10.1007/s13760-014-0308-9. Epub 2014 Jun 11.

PMID:
24915752
4.

Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study.

Lanzillo R, Quarantelli M, Bonavita S, Ventrella G, Lus G, Vacca G, Prinster A, Orefice G, Tedeschi G, Brescia Morra V.

Acta Neurol Scand. 2012 Nov;126(5):306-14. doi: 10.1111/j.1600-0404.2011.01622.x. Epub 2011 Nov 23.

PMID:
22107083
5.

The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.

Calabresi PA, Giovannoni G, Confavreux C, Galetta SL, Havrdova E, Hutchinson M, Kappos L, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Rudick RA, Stuart WH, Lublin FD, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA; AFFIRM and SENTINEL Investigators.

Neurology. 2007 Oct 2;69(14):1391-403. Epub 2007 Aug 29.

PMID:
17761550
6.

Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS.

Weinstock-Guttman B, Galetta SL, Giovannoni G, Havrdova E, Hutchinson M, Kappos L, O'Connor PW, Phillips JT, Polman C, Stuart WH, Lynn F, Hotermans C.

J Neurol. 2012 May;259(5):898-905. doi: 10.1007/s00415-011-6275-7. Epub 2011 Oct 19.

PMID:
22008873
7.

Treatment effect of natalizumab on relapse outcomes in multiple sclerosis patients despite ongoing MRI activity.

Bates D, Bartholomé E.

J Neurol Neurosurg Psychiatry. 2012 Jan;83(1):55-60. doi: 10.1136/jnnp-2011-300279. Epub 2011 Aug 23.

PMID:
21865211
8.

MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study.

Fox RJ, Cree BA, De Sèze J, Gold R, Hartung HP, Jeffery D, Kappos L, Kaufman M, Montalbán X, Weinstock-Guttman B, Anderson B, Natarajan A, Ticho B, Duda P; RESTORE.

Neurology. 2014 Apr 29;82(17):1491-8. doi: 10.1212/WNL.0000000000000355. Epub 2014 Mar 28. Erratum in: Neurology. 2015 Feb 24;84(8):862. multiple investigator names added.

9.

Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis.

Prosperini L, Giannì C, Leonardi L, De Giglio L, Borriello G, Galgani S, Pozzilli C, Gasperini C.

Mult Scler. 2012 Jan;18(1):64-71. doi: 10.1177/1352458511417481. Epub 2011 Aug 9.

PMID:
21828195
10.

Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.

Zivadinov R, Dwyer MG, Hussein S, Carl E, Kennedy C, Andrews M, Hojnacki D, Heininen-Brown M, Willis L, Cherneva M, Bergsland N, Weinstock-Guttman B.

Mult Scler. 2012 Aug;18(8):1125-34. doi: 10.1177/1352458511433304. Epub 2011 Dec 22.

PMID:
22194217
11.

[Natalizumab in the treatment of multiple sclerosis].

Horga A, Horga de la Parte JF.

Rev Neurol. 2007 Sep 1-15;45(5):293-303. Review. Spanish.

12.

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study.

Havrdova E, Galetta S, Hutchinson M, Stefoski D, Bates D, Polman CH, O'Connor PW, Giovannoni G, Phillips JT, Lublin FD, Pace A, Kim R, Hyde R.

Lancet Neurol. 2009 Mar;8(3):254-60. doi: 10.1016/S1474-4422(09)70021-3. Epub 2009 Feb 7.

PMID:
19201654
13.

Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab.

Rossi S, Motta C, Studer V, De Chiara V, Barbieri F, Monteleone F, Fornasiero A, Coarelli G, Bernardi G, Cutter G, Stüve O, Salvetti M, Centonze D.

Eur J Neurol. 2013 Jan;20(1):87-94. doi: 10.1111/j.1468-1331.2012.03794.x. Epub 2012 Jun 28.

PMID:
22741530
15.

Natalizumab reduces relapse clinical severity and improves relapse recovery in MS.

Lublin FD, Cutter G, Giovannoni G, Pace A, Campbell NR, Belachew S.

Mult Scler Relat Disord. 2014 Nov;3(6):705-11. doi: 10.1016/j.msard.2014.08.005. Epub 2014 Sep 6.

16.

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.

Hutchinson M, Kappos L, Calabresi PA, Confavreux C, Giovannoni G, Galetta SL, Havrdova E, Lublin FD, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Rudick RA, Stuart WH, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA; AFFIRM and SENTINEL Investigators.

J Neurol. 2009 Mar;256(3):405-15. doi: 10.1007/s00415-009-0093-1. Epub 2009 Mar 18. Erratum in: J Neurol. 2009 Jun;256(6):1035-7.

PMID:
19308305
17.

Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study).

Clerico M, Schiavetti I, De Mercanti SF, Piazza F, Gned D, Brescia Morra V, Lanzillo R, Ghezzi A, Bianchi A, Salemi G, Realmuto S, Sola P, Vitetta F, Cavalla P, Paolicelli D, Trojano M, Sormani MP, Durelli L.

JAMA Neurol. 2014 Aug;71(8):954-60. doi: 10.1001/jamaneurol.2014.1200.

PMID:
24977406
18.

Health-related quality of life in multiple sclerosis: effects of natalizumab.

Rudick RA, Miller D, Hass S, Hutchinson M, Calabresi PA, Confavreux C, Galetta SL, Giovannoni G, Havrdova E, Kappos L, Lublin FD, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Stuart WH, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA; AFFIRM and SENTINEL Investigators.

Ann Neurol. 2007 Oct;62(4):335-46.

PMID:
17696126
19.

Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study.

O'Connor P, Goodman A, Kappos L, Lublin F, Polman C, Rudick RA, Hauswirth K, Cristiano LM, Forrestal F, Duda P.

Neurology. 2014 Jul 1;83(1):78-86. doi: 10.1212/WNL.0000000000000541. Epub 2014 Jun 4. Erratum in: Neurology. 2014 Aug 19;83(8):773.

20.

An observational study of the effectiveness and safety of natalizumab in the treatment of multiple sclerosis.

Horga A, Castillo J, Rio J, Tintore M, Auger C, Sastre-Garriga J, Edo MC, Perez-Miralles F, Tur C, Nos C, Huerga E, Comabella M, Rovira A, Montalban X.

Rev Neurol. 2011 Mar 16;52(6):321-30. English, Spanish.

Supplemental Content

Support Center